Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An inherited autosomal recessive syndrome characterized by the disorganized formation of new islets in the pancreas and congenital hyperinsulinism. It is due to focal hyperplasia of pancreatic islet cells budding off from the ductal structures and forming new islets of langerhans. Mutations in the islet cells involve the potassium channel gene kcnj11 or the atp-binding cassette transporter gene abcc8, both on chromosome 11.
No HPO annotations are available for this condition.
Diabetes mellitus. Permanent neonatal diabetes mellitus (PNDM) is characterized by the onset of hyperglycemia within the first six months of life, with a mean age at diagnosis of seven weeks (range: birth to age 26 weeks) . Clinical manifestations at diagnosis include intrauterine growth restriction (IUGR; a reflection of insulin deficiency in utero), hyperglycemia, glycosuria, osmotic polyuria, severe dehydration, and poor weight gain. The diabetes mellitus is associated with partial or complete insulin deficiency. Therapy with insulin corrects the hyperglycemia and results in dramatic catch-up growth. Many individuals with ABCC8- or KCNJ11-related PNDM have improved glycemic control with sulfonylureas alone or combined with insulin treatment.
Permanent neonatal diabetes mellitus (PNDM) should be suspected in individuals with the following laboratory and radiographic features.
Laboratory features
Persistent hyperglycemia (plasma glucose concentration 250mg/dL) in infants younger than age six months that lasts for longer than seven to ten days
Features typical of diabetes mellitus (e.g., glucosuria, ketonuria, hyperketonemia)
No approved treatments are currently available for hyperinsulinemic hypoglycemia. An additional 2 compounds hold orphan drug designation.
While no drugs are FDA-approved specifically for hyperinsulinemic hypoglycemia, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for hyperinsulinemic hypoglycemia. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor |
|---|
To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations summarized in are recommended. Table 7. Permanent Neonatal Diabetes Mellitus: Recommended Surveillance
2 clinical trials registered. Interventions under study include other interventions. Pipeline includes 1 NA. Research is primarily sponsored by academic and government institutions.
147 publications have been identified in PubMed for hyperinsulinemic hypoglycemia. Research spans Case Report / Case Series (59%), Basic Science / Preclinical (11%), and Review / Meta-Analysis (10%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 86 | 59% |
Data assembled from 6 of 12 sources · Last updated Sep 18, 2026, 7:29 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Source: GeneReviews — "Permanent Neonatal Diabetes Mellitus"
Low or undetectable plasma insulin and C peptide relative to the hyperglycemia
Low fecal elastase and high stool fat in infants with pancreatic aplasia or hypoplasia due to pancreatic exocrine insufficiency
Source: GeneReviews — "Permanent Neonatal Diabetes Mellitus"
Permanent neonatal diabetes mellitus (PNDM) vs transient neonatal diabetes mellitus (TNDM). When diabetes mellitus is diagnosed in the neonatal period, it is difficult to determine if it is likely to be transient or permanent. The most common causes of TNDM are 6q24-related TNDM and ABCC8- or KCNJ11-related TNDM. • 6q24-related TNDM is caused by overexpression of the imprinted genes at 6q24 (PLAGL1 and HYMAI). The cardinal features are severe intrauterine growth restriction, hyperglycemia that begins in the neonatal period in a term infant and resolves by age 18 months, dehydration, and absence of ketoacidosis. Macroglossia and umbilical hernia may be present. 6q24-related TNDM associated with a multilocus imprinting disturbance (MLID) can be associated with marked hypotonia, congenital heart disease, deafness, macroglossia, neurologic features including epilepsy, and kidney malformations. Diabetes mellitus lasts on average three months but can last more than a year. Although insulin is usually required initially, the need for insulin gradually declines over time. Intermittent episodes of hyperglycemia may occur in childhood, particularly during intercurrent illnesses. Diabetes mellitus may recur in adolescence or later in adulthood. Women who have had 6q24-related TNDM are at risk for relapse during pregnancy. • Activating pathogenic variants in ABCC8 and KCNJ11 with less severe effects on beta cell KATP channel function have been found to cause TNDM that is similar to the biphasic course seen in 6q24-related TNDM. Typically, infants with ABCC8- or KCNJ11-related TNDM present before age six months, go into remission between ages six and 12 months, and are likely to relapse during adolescence or early adulthood . For infants with PNDM and extra-pancreatic features, consideration of syndromic PNDM may be appropriate . Table 4. Syndromic Permanent Neonatal Diabetes Mellitus
Gene | Disorder | MOI | Distinctive Features (in addition to neonatal DM) |
|---|---|---|---|
CNOT1 | Holoprosencephaly ± pancreatic agenesis (OMIM 618500) | AD | PNDM; Pancreatic agenesis; Holoprosencephaly; Gallbladder agenesis |
CTLA4 | Immune dysregulation w/autoimmunity, immunodeficiency, lymphoproliferation (OMIM 616100) | AD | PNDM; Lymphoproliferative syndrome; Enteropathy; Cytopenias |
Thyroiditis EIF2B11 | Neonatal/early-onset DM transient hepatic dysfunction | AD | PNDM; Transient hepatitis FOXP3 |
IPEX syndrome | XL | Enteropathy; Dermatitis | — |
GATA4 | GATA4-related PNDM2 | AD | Pancreatic exocrine insufficiency/agenesis; Cardiac abnormalities |
IER3IP1 | Neonatal DM, microcephaly, lissencephaly, epileptic encephalopathy (OMIM 614231) | AR | — |
IL2RA | Neonatal DM immune dysfunction (OMIM 606367) | AR | PNDM; Congenital hypothyroidism |
Sepsis3 ITCH4 | Neonatal DM systemic autoimmunity | AR | PNDM; Dysmorphic facies; Widespread autoimmunity ... |
Source: GeneReviews — "Permanent Neonatal Diabetes Mellitus"
Biomarker and diagnostic research for hyperinsulinemic hypoglycemia has been reported in the published literature.
Designated
Exclusivity End |
|---|
Designation Status |
|---|
glucagon (ready-to-use) | glucagon (ready-to-use) | Xeris Pharmaceuticals, Inc. | 2018 | — | Designated |
avexitide | avexitide | Amylyx Pharmaceuticals, Inc. | 2016 | — | Designated |
No clinical practice guidelines for permanent neonatal diabetes mellitus (PNDM) have been published. General guidelines for treatment of neonatal diabetes are available in the ISPAD Clinical Guidelines for Permanent Neonatal Diabetes . In the absence of published guidelines, the following recommendations are based on the authors' personal experience managing individuals with this disorder.
To establish the extent of disease and needs in an individual diagnosed with PNDM, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended.
Table 5.
Permanent Neonatal Diabetes Mellitus: Recommended Evaluations Following Initial Diagnosis
System/Concern | Evaluation | Comment
| Pediatric endocrinology eval/referral for acute long-term DM mgmt |
| Kidney ultrasound for evidence of cystic kidney disease or dysplasia | In persons w/HNF1B-related PNDM
| • Developmental eval
Neurology eval EEG in those w/suspected seizures
| In those w/KCNJ11-, MNX1-, NEUROD1-, NKX2-2-related PNDM
| • Imaging of pancreas
Eval of pancreatic exocrine function (fecal elastase, serum concentrations of fat-soluble vitamins)
| In those w/HNF1B-, PDX1-, PTF1A-, RFX6-related PNDM
| By genetics professionals1 | To obtain a pedigree inform affected persons their families re nature, MOI, implicati...
Source: GeneReviews — "Permanent Neonatal Diabetes Mellitus"
In general, rapid-acting insulin preparations (lispro and aspart) as well as short-acting (regular) insulin preparations should be avoided (except when used as a continuous intravenous or subcutaneous infusion), as they may cause severe hypoglycemic events in young children.
Source: GeneReviews — "Permanent Neonatal Diabetes Mellitus"
Search ClinicalTrials.gov in the and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "Permanent Neonatal Diabetes Mellitus"
2 trials found
Evaluation |
|---|
Frequency |
|---|
Diabetes mellitus | Blood glucose concentrations to avoid acute complications such as diabetic ketoacidosis hypoglycemia | Frequent monitoring in hospital immediately following diagnosis; Lifelong monitoring (≥4x/day or w/continuous glucose monitor) after stabilization on treatment Kidney manifestations |
Ocular manifestations of DM | Ophthalmologic exam to assess for retinopathy | Annually beginning at age 10 yrs |
Development | Developmental eval | Annually or as needed in those w/KCNJ11-, MNX1-, NEUROD1-, NKX2-2-related PNDM |
Seizures | Neurology eval EEG | As needed in those w/KCNJ11-related DEND syndrome |
Exocrine pancreatic insufficiency | Eval of pancreatic exocrine function (fecal elastase, serum concentrations of fat-soluble vitamins) | As needed in those w/symptoms of malabsorption DEND = developmental delay, epilepsy, and neonatal diabetes mellitus; DM = diabetes mellitus; PNDM = permanent neonatal diabetes mellitus |
Source: GeneReviews — "Permanent Neonatal Diabetes Mellitus"
Laboratory research |
16 |
11% |
Research summaries | 14 | 10% |
Clinical study results | 13 | 9% |
Disease patterns and progression | 12 | 8% |
Testing and diagnosis research | 4 | 3% |
Other research | 1 | 1% |
New treatment approaches | 1 | 1% |
Hinrichs A (2026). [PMID: 41125144](https://pubmed.ncbi.nlm.nih.gov/41125144/). *Mol Metab*. [Basic Science / Preclinical]
Nair AK (2026). [PMID: 41291239](https://pubmed.ncbi.nlm.nih.gov/41291239/). *Diabetologia*. [Basic Science / Preclinical]
Athavale A (2026). [PMID: 37276276](https://pubmed.ncbi.nlm.nih.gov/37276276/). *Unknown Journal*. [Review / Meta-Analysis]
Nahar S (2026). [PMID: 42143009](https://pubmed.ncbi.nlm.nih.gov/42143009/). *Dis Mon*. [Review / Meta-Analysis]
Yang D (2026). [PMID: 42121233](https://pubmed.ncbi.nlm.nih.gov/42121233/). *Nutr Metab (Lond)*. [Other]
Widmer A (2026). [PMID: 40705962](https://pubmed.ncbi.nlm.nih.gov/40705962/). *The Journal of clinical endocrinology and metabolism*. [Epidemiology / Natural History]
Mitteer LM (2026). [PMID: 42149805](https://pubmed.ncbi.nlm.nih.gov/42149805/). *Horm Res Paediatr*. [Case Report / Case Series]
Yoshida H (2026). [PMID: 41833398](https://pubmed.ncbi.nlm.nih.gov/41833398/). *Endocr J*. [Case Report / Case Series]
Ferraz-Bannitz R (2026). [PMID: 41806840](https://pubmed.ncbi.nlm.nih.gov/41806840/). *Cell Rep Med*. [Basic Science / Preclinical]
Collins LC (2026). [PMID: 41634357](https://pubmed.ncbi.nlm.nih.gov/41634357/). *J Perinatol*. [Epidemiology / Natural History]